## Co-expression network analysis identified FCER1G in association with

 progression and prognosis in human clear cell renal cell carcinomaLiang Chen, Lushun Yuan, Yongzhi Wang, Gang Wang, Yuan Zhu, Rui Cao,

Guofeng Qian, Conghua Xie, Xuefeng Liu, Yu Xiao, Xinghuan Wang

## Supplementary Information 1



Supplementary Figure 1. Samples clustering and FCER1G expression in the two testing datasets. (A) Total samples clustering of GSE66272 to detect outliers. One sarcoma sample GSM1618417 with red marker was removed from the subsequent analysis. (B-C) FCER1G mRNA expression was significantly higher in ccRCC tissues compared with normal kidney tissues based on the microarray dataset GSE53757 (B) and TCGA RNA sequencing dataset (C). Two-tailed Student's $t$-test was used for significance of differences between subgroups, *** $\mathrm{p}<0.001$.

## Supplementary Information 2

Supplementary Table 1. Clinical information of ccRCC patients in training dataset and testing dataset.

| Characteristics | Training dataset GSE66272 | Testing dataset GSE53757* | Testing dataset TCGA** |
| :---: | :---: | :---: | :---: |
| Age |  |  |  |
| $\geq 65$ | 13 | - | - |
| < 65 | 13 | - | - |
| Sex |  |  | - |
| Female | 8 | - | - |
| Male | 18 | - | - |
| Pathological stage |  |  |  |
| Stage I | 12 | 24 | 261 |
| Stage II | 1 | 19 | 56 |
| Stage III | 12 | 14 | 123 |
| Stage IV | 1 | 15 | 82 |
| Tumor grade |  |  |  |
| Grade 1 | 1 | - | - |
| Grade 2 | 16 | - | - |
| Grade 3 | 8 | - | - |
| Grade 4 | 1 | - | - |
| Metastasis | 1 | - | - |
| Yes | 12 | - | - |
| No | 14 | - | - |

*In both GSE53757 and TCGA datasets, only pathological stage was used in our analysis.
"The testing dataset TCGA contained 539 ccRCC tissue samples, of which 522 samples have definite pathological stage.

Supplementary Table 2. Correlation between FCER1G and clinical parameters in ccRCC.

| Characteristics | Number of cases | FCER1G expression |  | $\mathbf{P}$ value |
| :---: | :---: | :---: | :---: | :---: |
|  |  | Low (n=13) | High ( $\mathrm{n}=13$ ) |  |
| Age |  |  |  |  |
| $\geq 65$ | 13 | 7 | 6 | 0.694 |
| < 65 | 13 | 6 | 7 |  |
| Gender |  |  |  |  |
| Male | 18 | 9 | 9 | 1 |
| Female | 8 | 4 | 4 |  |
| Tumor stage |  |  |  |  |
| Stage I-II | 12 | 5 | 7 | 0.239 |
| Stage III-IV | 14 | 8 | 6 |  |
| Tumor grade |  |  |  |  |
| Grade 1, 2 | 17 | 6 | 11 | 0.039* |
| Grade 3, 4 | 9 | 7 | 2 |  |
| Metastasis |  |  |  |  |
| Yes | 12 | 10 | 2 | 0.0016** |
| No | 14 | 3 | 11 |  |

